Table 1 Characteristics of the three groups
Men | Women < 50 | Women ≥ 50 | p value | |
|---|---|---|---|---|
Number of patients | 38 | 42 | 105 | |
Age (years) | 57 [46–68] | 37 [30–46] | 64 [55–68] | < 0.0001 |
pSS | 16 (42.1%) | 16 (38.1%) | 61 (58.1%) | 0.048 |
Treatments inducing oral and/or ocular dryness | 5 (13.2%) | 10 (23.8%) | 28 (26.7%) | 0.24 |
Subjective DES | 28 (73.7%) | 40 (95.2%) | 95 (90.5%) | < 0.01 |
Schirmera (mm/5 min) | 1 [0–3] | 5 [1–17.3] | 1 [0–4] | < 0.001 |
Schirmer ≤ 5 mm/5 min | 33 (86.8%) | 25 (59.5%) | 90 (85.7%) | < 0.001 |
OSS realization | 10 (26.3%) | 10 (23.8%) | 29 (27.6%) | 0.69 |
OSS ≥ 5 (if examination was realized)b | 1/10 (10.0%) | 2/10 (20.0%) | 8/29 (27.6%) | 0.51 |
Subjective DMS | 30 (78.9%) | 37 (88.1%) | 99 (94.3%) | 0.026 |
UWS flow (mL/min) | 0.27 [0.08–0.42] | 0.21 [0.09–0.46] | 0.20 [0.07–0.33] | 0.25 |
UWS flow rate ≤ 0.1 mL/min | 11 (28.9%) | 13 (31.0%) | 40 (38.1%) | 0.51 |
Anti-SSA antibodies | 4 (10.5%) | 9 (21.4%) | 22 (21.0%) | 0.35 |
Anti-SSB antibodies | 5 (13.2%) | 6 (14.3%) | 16 (15.2%) | 0.95 |
ANA > 1/200 | 12 (31.6%) | 12 (28.6%) | 32 (30.5%) | 0.96 |
Focus score ≥ 1 on MSGB | 15 (39.5%) | 17 (40.5%) | 61 (58.1%) | 0.051 |